Plus Therapeutics (PSTV)
NASDAQ:PSTV
Top Page
Plus Therapeutics
(NASDAQ:PSTV)
Select Model
Select Model
Rating:40Underperform
Price Target:
$3.00
▲(417.24% Upside)
Action:DowngradedDate:04/10/26
The score is held down primarily by very weak financial performance (zero 2025 revenue, widening losses, and accelerating cash burn) and a strongly bearish technical trend (price well below key moving averages with negative MACD). Positive corporate developments (orphan designation and leadership additions) provide some support, but valuation is not compelling given ongoing losses and no dividend.
Positive Factors
Orphan Drug Designation
Orphan designation gives REYOBIQ potential market exclusivity, tax credits and fee reductions, materially improving regulatory and commercial economics for rare CNS indications. This strengthens long-term partner appeal and de-risks elements of the approval/commercial pathway for the lead program.
Negative Factors
No revenue and widening losses
Zero 2025 revenue and materially wider net losses indicate the company remains pre-commercial and highly dependent on achieving clinical success. Persistent operating losses reduce internal funding capacity, increasing reliance on external financing and raising execution and dilution risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Orphan Drug Designation
Orphan designation gives REYOBIQ potential market exclusivity, tax credits and fee reductions, materially improving regulatory and commercial economics for rare CNS indications. This strengthens long-term partner appeal and de-risks elements of the approval/commercial pathway for the lead program.
Read all positive factors
Plus Therapeutics (PSTV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$32.94M
Dividend YieldN/A
Average Volume (3M)393.75K
Price to Earnings (P/E)―
Beta (1Y)1.35
Revenue Growth-8.16%
EPS Growth22.44%
CountryUS
Employees21
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.83
Shares Outstanding6,862,027
10 Day Avg. Volume885,984
30 Day Avg. Volume393,750
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)9.98
Price to Sales (P/S)7.65
P/FCF Ratio-1.91
Enterprise Value/Market Cap0.11
Enterprise Value/Revenue0.71
Enterprise Value/Gross Profit0.77
Enterprise Value/Ebitda-0.25
Forecast
1Y Price Target
$5.00Price Target Upside762.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-3.43
Revenue Forecast (FY)$6.23M
Plus Therapeutics Business Overview & Revenue Model
Company Description
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a pate...
How the Company Makes Money
As a clinical-stage biotechnology company, Plus Therapeutics has historically not generated material recurring revenue from commercial product sales; its ability to make money in the future is primarily tied to successfully developing, obtaining r...
Plus Therapeutics Earnings Call Summary
Earnings Call Date:Mar 27, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Apr 16, 2026
Earnings Call Sentiment Positive
The earnings call presented a mix of promising clinical trial results, successful financing, and strategic acquisitions that position Plus Therapeutics for future growth. However, these positives were offset by an increase in operating loss and a decline in cash reserves. The overall sentiment leans towards optimism due to strong forward-looking developments.Positive Updates
Successful Financing and Partnerships
Plus Therapeutics raised $15 million in an underwritten equity financing and received $2 million in accelerated grant proceeds from CPRIT. This strengthens the balance sheet and provides funding through mid-2026. Partnerships with SpectronRX, IsoTherapeutics, RadioMedix, and ABX were also announced to ensure supply chain management for REYOBIQ.
Negative Updates
Operating Loss Increase
The company reported an operating loss of $14.7 million in 2024, up from $13.3 million in 2023, primarily due to increased spending related to the ReSPECT-LM trial.
Read all updates
Q4-2024 Updates
Positive
Negative
Successful Financing and Partnerships
Plus Therapeutics raised $15 million in an underwritten equity financing and received $2 million in accelerated grant proceeds from CPRIT. This strengthens the balance sheet and provides funding through mid-2026. Partnerships with SpectronRX, IsoTherapeutics, RadioMedix, and ABX were also announced to ensure supply chain management for REYOBIQ.
Read all positive updates
Company Guidance
In the recent Plus Therapeutics' Fourth Quarter and Full Year 2024 Results Conference Call, the company provided extensive guidance on its financial and clinical milestones. The company completed a $15 million equity financing and received $2 million in accelerated grant proceeds from CPRIT, securing funding through mid-2026. Key clinical updates included the completion of the ReSPECT-LM Phase 1 trial, establishing a recommended Phase 2 dose of 44 millicuries for their lead drug REYOBIQ, which showed promising safety and efficacy data. Plus Therapeutics plans to conduct an end-of-Phase 1 meeting with the FDA to finalize the path to approval, especially for LM related to breast cancer. Additionally, the company aims to advance its CNSide diagnostics platform, projecting significant market potential and a planned full launch within the year. Financially, the company reported a net loss of $13 million for 2024, compared to $13.3 million in 2023, and highlighted an expected 2025 grant revenue of $6 to $8 million.Plus Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
28
Negative
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.21M | 5.82M | 4.91M | 224.00K | 0.00 |
| Gross Profit | 4.77M | 4.97M | -4.78M | -488.00K | -66.00K |
| EBITDA | -14.85M | -8.40M | -12.69M | -18.85M | -12.05M |
| Net Income | -22.39M | -12.98M | -13.32M | -20.27M | -13.40M |
Balance Sheet | |||||
| Total Assets | 16.32M | 6.63M | 11.39M | 23.87M | 21.98M |
| Cash, Cash Equivalents and Short-Term Investments | 8.76M | 3.61M | 8.55M | 18.12M | 18.40M |
| Total Debt | 821.00K | 3.37M | 4.18M | 5.75M | 6.99M |
| Total Liabilities | 12.33M | 15.58M | 12.74M | 17.42M | 11.14M |
| Stockholders Equity | 4.00M | -8.95M | -1.35M | 6.45M | 10.84M |
Cash Flow | |||||
| Free Cash Flow | -20.84M | -10.70M | -13.01M | -13.73M | -10.42M |
| Operating Cash Flow | -20.77M | -10.55M | -12.85M | -12.97M | -10.28M |
| Investing Cash Flow | -854.00K | -4.11M | -160.00K | -759.00K | -82.00K |
| Financing Cash Flow | 30.31M | 6.19M | 3.44M | 13.45M | 20.42M |
Plus Therapeutics Technical Analysis
Neutral
0.58
Price Trends
6.20
Negative
9.55
Negative
11.36
Negative
Market Momentum
-0.89
Positive
44.80
Neutral
36.03
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PSTV, the sentiment is Neutral. The current price of 0.58 is below the 20-day moving average (MA) of 5.11, below the 50-day MA of 6.20, and below the 200-day MA of 11.36, indicating a bearish trend. The MACD of -0.89 indicates Positive momentum. The RSI at 44.80 is Neutral, neither overbought nor oversold. The STOCH value of 36.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PSTV.
Plus Therapeutics Risk Analysis
Plus Therapeutics disclosed 54 risk factors in its most recent earnings report. Plus Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Plus Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $60.44M | -1.19 | -53.71% | ― | ― | 21.17% | |
47 Neutral | $180.35M | -0.32 | 77.87% | ― | -3.98% | -29.94% | |
44 Neutral | $23.18M | -0.43 | -70.57% | ― | -100.00% | -26.30% | |
43 Neutral | $27.19M | -3.81 | -197.68% | ― | ― | 78.60% | |
41 Neutral | $27.21M | -1.38 | -135.79% | ― | -53.67% | 86.75% | |
40 Underperform | $32.94M | -1.74 | 774.80% | ― | -8.16% | 22.44% |
* Healthcare Sector Average
PSTV
Plus Therapeutics
4.80
-11.19
-69.98%
KPTI
Karyopharm Therapeutics
8.00
3.79
90.02%
TVRD
Tvardi Therapeutics
2.90
-13.75
-82.58%
BRNS
Barinthus Biotherapeutics
0.57
-0.13
-18.88%
SNTI
Senti Biosciences
0.87
-2.41
-73.41%
ACRV
Acrivon Therapeutics, Inc.
1.56
0.06
4.00%
Plus Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Plus Therapeutics Appoints New Chief Development Officer
Positive
Apr 9, 2026
On April 9, 2026, Plus Therapeutics announced the appointment of Eric J. Daniels, M.D., as chief development officer, effective April 20, 2026, tasking him with overseeing development and ultimate approval of the company’s pharmaceutical pip...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Plus Therapeutics Gains FDA Orphan Status for REYOBIQ
Positive
Apr 8, 2026
On April 8, 2026, Plus Therapeutics announced that the U.S. Food and Drug Administration granted Orphan Drug Designation to its lead radiotherapeutic candidate REYOBIQ for the treatment of pediatric malignant gliomas, with the designation applying...
Delistings and Listing ChangesRegulatory Filings and ComplianceStock Split
Plus Therapeutics Enacts Reverse Stock Split to Maintain Listing
Neutral
Apr 2, 2026
Plus Therapeutics has implemented a 1-for-25 reverse stock split of its common stock, converting every 25 issued and outstanding shares into one share without changing the $0.001 par value or stockholder voting rights. The move, approved by stockh...
Business Operations and StrategyExecutive/Board Changes
Plus Therapeutics Adds Industry Veteran Ronald Andrews to Board
Positive
Mar 26, 2026
On March 20, 2026, Plus Therapeutics, Inc. appointed industry veteran Ronald A. Andrews as an independent director to its board, filling the vacancy created by the resignation of Dr. Robert Lenk, who left without any disagreement over the company&...
Shareholder Meetings
Plus Therapeutics Sets 2026 Virtual Annual Stockholder Meeting
Neutral
Mar 12, 2026
On March 11, 2026, Plus Therapeutics’ board set the company’s 2026 Annual Meeting of Stockholders for Thursday, May 14, 2026, at 9:00 a.m. Eastern Time, to be held virtually by remote communication, with stockholders of record as of th...
Executive/Board ChangesFinancial DisclosuresRegulatory Filings and Compliance
Plus Therapeutics Updates Executive Compensation, Approves 2025 Bonuses
Neutral
Feb 13, 2026
On January 9, 2026, Plus Therapeutics filed a registration statement that initially omitted 2025 discretionary cash bonus amounts for certain named executive officers, indicating these would be reported once determined. On February 9, 2026, the bo...
Business Operations and Strategy
Plus Therapeutics Sharpens Focus on CNS Cancer Strategy
Positive
Jan 22, 2026
On January 22, 2026, Plus Therapeutics updated its corporate presentation for investors, outlining an intensified strategic focus on CNS cancers, an area where metastases now outnumber primary brain cancers by roughly ten to one and survival impro...
Business Operations and StrategyPrivate Placements and Financing
Plus Therapeutics completes underwritten public equity offering
Neutral
Jan 16, 2026
On January 13, 2026, Plus Therapeutics entered into an underwriting agreement with Lake Street Capital Markets for an underwritten public offering of 39,473,684 shares of common stock and an equal number of warrants at $0.38 per unit, with a 30-da...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.